These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
967 related articles for article (PubMed ID: 16096010)
1. In vivo application of RNA interference: from functional genomics to therapeutics. Lu PY; Xie F; Woodle MC Adv Genet; 2005; 54():117-42. PubMed ID: 16096010 [TBL] [Abstract][Full Text] [Related]
2. [Application of atelocollagen-mediated siRNA delivery for RNAi therapies]. Honma K; Takeshita F; Ochiya T Yakugaku Zasshi; 2007 May; 127(5):807-12. PubMed ID: 17473522 [TBL] [Abstract][Full Text] [Related]
3. RNA interference: from gene silencing to gene-specific therapeutics. Leung RK; Whittaker PA Pharmacol Ther; 2005 Aug; 107(2):222-39. PubMed ID: 15908010 [TBL] [Abstract][Full Text] [Related]
4. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Xie FY; Woodle MC; Lu PY Drug Discov Today; 2006 Jan; 11(1-2):67-73. PubMed ID: 16478693 [TBL] [Abstract][Full Text] [Related]
5. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Hong CA; Nam YS Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170 [TBL] [Abstract][Full Text] [Related]
6. Selective gene silencing by viral delivery of short hairpin RNA. Sliva K; Schnierle BS Virol J; 2010 Sep; 7():248. PubMed ID: 20858246 [TBL] [Abstract][Full Text] [Related]
7. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery. Keates AC; Fruehauf J; Xiang S; Li CJ Biotechnol Genet Eng Rev; 2008; 25():113-27. PubMed ID: 21412352 [TBL] [Abstract][Full Text] [Related]
8. RNAi-based drug discovery and its application to therapeutics. Hokaiwado N; Takeshita F; Banas A; Ochiya T IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962 [TBL] [Abstract][Full Text] [Related]
9. RNAi: a novel antisense technology and its therapeutic potential. Dallas A; Vlassov AV Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063 [TBL] [Abstract][Full Text] [Related]
10. siRNA delivery systems for cancer treatment. Oh YK; Park TG Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of RNA interference against cancer. Takeshita F; Ochiya T Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503 [TBL] [Abstract][Full Text] [Related]
12. shRNA and siRNA delivery to the brain. Pardridge WM Adv Drug Deliv Rev; 2007 Mar; 59(2-3):141-52. PubMed ID: 17434235 [TBL] [Abstract][Full Text] [Related]
13. Overcoming obstacles to develop effective and safe siRNA therapeutics. Li L; Shen Y Expert Opin Biol Ther; 2009 May; 9(5):609-19. PubMed ID: 19392577 [TBL] [Abstract][Full Text] [Related]
14. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817 [TBL] [Abstract][Full Text] [Related]
16. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics. Zhou Y; Zhang C; Liang W J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071 [TBL] [Abstract][Full Text] [Related]
17. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Akhtar S; Benter I Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774 [TBL] [Abstract][Full Text] [Related]
18. Development of new RNAi therapeutics. Liu G; Wong-Staal F; Li QX Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694 [TBL] [Abstract][Full Text] [Related]